Investigators working at the National Synchrotron Light Source (NSLS) at the Brookhaven National Laboratory discovered new peptides that seem to block the entry of HIV particles into cells quite effectively:
“Our ‘D-peptides’ offer several potential therapeutic advantages over existing peptide entry inhibitors, which are costly, require high dose injections, and suffer from the emergence of drug-resistance,” said University of Utah biochemist Michael S. Kay, lead author on the paper. “In contrast, our D-peptides resist degradation, so they have the potential to be administered by mouth and last longer in the bloodstream. Since these inhibitors have a unique inhibitory mechanism, they should work well in combination with existing HIV inhibitors.”
The researchers were particularly interested in developing drugs to bind to an essential “pocket” structure found in all HIV strains that was previously identified as a promising drug target using structures determined at Brookhaven’s NSLS. Numerous previous attempts to target this pocket failed to produce potent and non-toxic pocket-specific entry inhibitors. In the current work, the researchers used a high-throughput technique to screen a “library” containing hundreds of millions of peptides to identify the rare peptides that would bind to the pocket structure and inhibit HIV entry.
After identifying the most promising candidate peptides, the researchers analyzed the structure of these peptides bound to the target protein using x-ray crystallography at the NSLS. In this technique, researchers analyze how an extremely bright beam of x-rays, available only at synchrotron sources, bounces off and is refracted by the sample to determine the positions of individual atoms. “These structures reveal details of how the peptides bind and guide the development of future inhibitors,” said paper co-author Annie Heroux, a biologist and crystallography specialist at Brookhaven Lab.
This structure-assisted design led to the discovery of D-peptides with up to a 40,000-fold improved antiviral potency over previously reported D-peptides. The structures also suggest ways to engineer the peptides to reduce the chance of drug resistance.
More from Brookhaven National Lab…
